ReviewExpert opinion on biological therapy2009
Cellular immunotherapy for ovarian cancer.
Review in Expert opinion on biological therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 29 citations in OpenAlex.
- Immunotherapy in Cervical and Endometrial Cancer: Current Landscape and Future Directions.Life (Basel, Switzerland) · 2024Review
- A novel method for efficient generation of antigen-specific effector T-cells using dendritic cells transduced with recombinant adeno-associated virus and p38 kinase blockade.Journal of translational medicine · 2019Article
- Tumor infiltrating lymphocytes in ovarian cancer.Cancer biology & therapy · 2015Review
- Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Immunotherapy in ovarian cancer.Human vaccines & immunotherapeutics · 2012Review
- Immunotherapy for ovarian cancer: what's next?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Review
- Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.Cancer management and research · 2011Article
- Whole tumor antigen vaccines.Seminars in immunology · 2010Review
- Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.PloS one · 2010Article
- Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes.Cell cycle (Georgetown, Tex.) · 2010Review
- Immunotherapy of cancer in 2012.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundOvarian cancer is frequently diagnosed at an advanced stage, and although initially responsive to surgery and chemotherapy, has a high rate of recurrence and mortality. Cellular immunotherapy may offer the prospect of treatment to prevent or delay recurrent metastatic disease.
objectiveTo provide an overview of current innovations in cellular immunotherapy for ovarian cancer, with an emphasis on dendritic cell vaccination and adoptive T-cell immunotherapy.
methodsThree key areas are explored in this review: first, an appraisal of the current state of the art of cellular immunotherapy for treatment of ovarian cancer; second, a discussion of the immunological defenses erected by ovarian cancer to prevent immunological attack, with an emphasis on the role of tumor-associated regulatory T cells; and third, an exploration of innovative techniques that may enhance the ability of cellular immunotherapy to overcome ovarian tumor-associated immune suppression. RESULTS/
conclusionOvarian cancer is recognized as a paradigm for tumor-associated immune suppression. Innovative approaches for antagonism of tumor-associated regulatory T-cell infiltration and redirection of self antigen-driven regulatory T-cell activation may provide the key to development of future strategies for cellular immunotherapy against ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.